What's Happening?
Circle Pharma has unveiled preclinical data from its cyclin D1 program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data demonstrate the potential of
Circle Pharma's oral macrocyclic inhibitors to disrupt the cyclin D1-Rb interaction, a key driver of cell cycle progression in various cancers. The inhibitors show strong selectivity and anti-tumor activity in models of mantle cell lymphoma and ER-positive breast cancer. The company plans to nominate a development candidate by the end of 2025, aiming to offer new therapeutic options for cyclin D1-driven cancers.
Why It's Important?
Circle Pharma's advancements in targeting cyclin D1 represent a significant step in cancer treatment, particularly for cancers where cyclin D1 is a major driver. The ability to selectively inhibit cyclin D1-Rb binding while sparing related isoforms could reduce hematologic toxicities associated with current therapies. This innovation has the potential to improve treatment outcomes and expand therapeutic options for patients with cyclin D1-driven cancers. As Circle Pharma progresses towards clinical development, its work could lead to new, effective cancer therapies, impacting patient care and the oncology drug market.
